CANCER TEST REQUISITION FORM



Cytogenetic Laboratories

Indiana University School of Medicine 975 W. Walnut, IB 350, Indianapolis, IN 46202 317/274-2243 (Office) 317/278-1616 (Fax)

Patient Laboratory Label

CAP#: 16789-30 CLIA#: 15D0647198

			CA1#, 10707-50 CE1A#, 15D0047170			
1) PHYSICIAN(S):			FOR LABORATORY USE ONLY:			
Referring Physician:			. D : 1			
		, D	ate Received:/			
City:	State: Zip:		me Received::_			
	Fax:	1 10	eceived By	Not Proband	1: ⊔	
riione.	Гах					
Drimary Dhygiaian				BM/DA: ☐ BM/RA:		
				Probes FISI Handling ONLY		
Phone:	Fax:					
		<u>Lal</u>	Comment(s): Vacs: gr	reen purple; Other:		
2) PATIENT INI	FORMATION:	<u> </u>				
Patient Name:	Last Name		First Name	Mi	ddle Initial	
Address:	Lust ivame			IVII	aate miitai	
Street			City	State	Zip Code	
Hospital:			Medical Record #:	•	•	
_						
Date of Birth:	/ Sex	: Male Femal	e If Post-Transplant, D	onor Sex: ☐ Male ☐ Fe	emale Autologous	
Mon	th Day Year	,	Olasta.			
WBC (A10'):	IEODMATION (D	0 NOT EDERGE 0	Blasts:		ELED)	
•			PECIMENS – ALL SPEC			
Collection Date:	/	Collection 7	Time:am/pm C	Collected By:		
	Month Day Year					
Referring Diagn	osis:					
4) SPECIMEN II	NFORMATION at	nd REQUESTE	D TESTING:			
☐ Bone Marrow (RO	OOM TEMP)		REQUESTED TESTIN	i G		
☐ Bone Core (ROOM				e Analysis (Karyotype) <u>ON</u>		
	or Leukemic Studies (RO			s & Fluorescence In Situ (S	elect Probe/Panel below)	
☐ Tumor / Type: ☐ Biliary Stricture	S	ıte:	☐ Fluorescence In Situ (FISH) Analysis <u>ONLY</u> STAT analysis (t(15;17) PN	II /DADA nucho (AVI V)	
☐ Urine (Bladder Ca	ncer)		in Thorescence in Situ S	51A1 alialysis (u(15,17)1 lv	il/KAKA probe <u>ONLT</u>)	
FISH Panels – Cance	•					
		:19), ABL2.	I MPN Panel: -5/del(5q), del(7	a). FISH Plasma Cel	l Myeloma Panel with	
	9p21, ABL1, t(9;22), KMT2A		t(9;22), 9q34, del(20q)	Reflex : 1q21, 5p, 5c		
☐ FISH ALL Panel – Adult (>18) with Ph-like Reflex: ☐ FISH AML Panel: inv(3), -5/del				13q14.2 (RB1)/13q14.3 (D13S319), IGH,		
	7cen, 9p21, t(9;22), KMT2A,		, del(7q), 8cen, t(8;21), KMT2A,		ex if IGH rearranged to and t(14;16) IGH::MAF	
	cludes ABL2, PDGFRB, AB (6q), t(11;14), ATM, 12cen,		7), t(16;16), del(20q) 17) Stat?□ Yes□ No	(',- ')	(- ',- ')	
_			I Lymphoma Panel: BCL6,	<u>UROVYSION</u>		
	del(200) *4ll in 4ML Panel MYC, t(14;18), reflex t(8;14) if MYC					
(D		abnor	mal	☐ FISH UroVysion	Panel (Urine)	
FISH PET – Cancer	/Oncology:		Individ	ual PET probes (each prob	e renerted congretaly)	
□FISH-HER2 Breast Ca		☐ FISH-PET Lymph		I-3q27 (BCL6)	e reported separately)	
□FISH-HER2 Gastroes		MYC, t(14;18), refle	· · · · · · · · · · · · · · · · · · ·	t(8;14) MYC:IGH		
☐FISH-HER2 Non-Brea	ast Tissue	abnormal		[8q24 (MYC)		
FISH Individual Prol	bes – Cancer/Oncolog	<u> </u>	□ FISH	I-t(14;18) IGH::BCL2		
□1q21,8p	□4q12 (PDGFRA,CHIC2)	 □8 Centromere,del(20q	□9q34 (ASS1)	□t(12;21) ETV6::RUNX1	□t(16;16) CBFB::MYH11	
□t(1;19) PBX1::TCF3	□4q12 (PDGFRA,CHIC2) □t(4;14) FGFR3::IGH	□8q24 (MYC)	□ t(11;14) CCND1::IGH	□13q14 (FOXO1)	□17p13.1 (TP53)	
□1q25.2 (ABL2)	□5q33.2 (PDGFRB)	□t(8;14) MYC::IGH	□t(11;18) BIRC3::MALT	* '	□17q21.1 (RARA)	
□2p23.2 (ALK)	□-5/del(5q)	$\Box t(8;21) \text{ RUNX1T1::R}$		□14q32.3 (IGH)	□del(20q),8 Centromere	
□2p24.1 (MYCN)	□t(6;9) DEK::NUP214	□9p21 (CDKN2A)	□11q23 (KMT2A)	□t(14;16) IGH::MAF	□22q12 (EWSR1)	
□3q27 (BCL6) □inv(3) RPN1::MECOM	\Box del(6q)	□9q34.1 (ABL1)	□12 Centromere	□t(14;18) IGH::BCL2	$\Box X/Y$	
	$\Box \operatorname{del}(7q)$	\Box t(9;22) BCR::ABL1	□12p13 (ETV6)	\Box t(15;17) PML::RARA	\square Xp22.3/Yp11.2 (CRLF2)	

Specimen	Collection	Container(s)	Instructions
Peripheral Blood for cancer analysis	7-10mL whole blood (adults) 2-4mL whole blood (infants)	Dark Green-top sodium heparin tube.	Keep at room temperature.
Bone Marrow Aspirate	0.5 mL minimum 2 mL preferred for normal WBC ↓ WBC requires more ↑ WBC requires less 1-2 mL preferred	Dark Green-top sodium heparin tube.	Keep at room temperature.
Formalin-fixed, Paraffin-Embedded Tissue (PET)	4-micron sections on positively charged, circled/marked slides (2-3 slides are sufficient) Corresponding H&E section with area of tumor marked. NO DECALCIFIED BONE!	Slides - NO BLOCKS	Copy of Pathology report and patient/hospital billing information MUST BE INCLUDED with slides.
Urine (Bladder Cancer) *For UroVysion Studies <u>ONLY</u> *	≥ 30 mL (50 mL preferred)	50 mL centrifuge tubes or other tightly capped plastic container.	Keep at room temperature. Include copy of pathology report.
Biliary Brushing *For UroVysion Studies <u>ONLY</u> *	Specimen from endoscopic retrograde cholangiopancreatography (ERCP) brushing	ThinPrep PreservCyt® Solution from Hologic (containers provided by the Cytogenetics Laboratory)	Keep at room temperature. Ship to laboratory within 24 hours. Refrigerat if there is a delay in shipping. Include copy of pathology report.

6) SPECIMEN HANDLING REQUIREMENTS

- Use sterile technique; close all containers tightly.
- Do not freeze any specimen type.
- Label all containers and requisition forms with patient name, MRN, date of collection, and physician name.
- Specimens should be received within 24 hours of collection.

7) PATIENT BILLING INFORMATION:			
☐ Bill Patient's Insurance: Policy #:		Group #:	
Insurance/Managed Care Plan:			
Street Address:	City:	State:	Zip:
Relationship to Insured: ☐ Self ☐ Spouse ☐ Oth	er:	_ Insured's Social Security #: _	
\square <u>OR</u> Copy of patient's insurance card attache	d		
☐ Bill Medicare:			
☐ Bill Medicaid:			
☐ Bill Patient/Self-Pay(Please Attach Patient Dem			
☐ Bill Hospital:			